C - Chemistry – Metallurgy – 07 – K
Patent
C - Chemistry, Metallurgy
07
K
C07K 16/24 (2006.01) A61K 39/00 (2006.01) A61K 39/385 (2006.01) A61K 39/395 (2006.01) A61P 11/00 (2006.01) A61P 37/02 (2006.01) A61P 37/08 (2006.01)
Patent
CA 2519313
The present invention relates to preventing, or treating and/or reducing the severity or progression of Type 1 immune response-mediated inflammatory lung disease. More particularly, the present invention provides a method for preventing or treating chronic obstructive pulmonary disease (COPD), severe asthma, sarcoidosis, berylliosis or cystic fibrosis by neutralizing or reducing IFN.gamma. bioactivity which can be achieved either by in vivo administration of IFN.gamma. neutralizing molecules or by in vivo immunization with pharmaceutical compositions comprising immunogenic IFN.gamma. proteins or IFN.gamma. -derived (poly)peptides or their corresponding nucleic acid sequences.
La présente invention permet de prévenir ou traiter et/ou réduire la sévérité ou la progression de la pneumopathie inflammatoire médiée par la réponse immunitaire de type 1. En particulier, l'invention concerne un procédé qui permet de prévenir ou traiter la bronchopneumopathie chronique obstructive (BPCO), l'asthme sévère, la sarcoidose, la berylliose ou la fibrose cystique en neutralisant ou en réduisant la bioactivité de l'IFN?, ce que l'on obtient par l'administration in vivo de molécules neutralisant l'IFN? ou par l'immunisation in vivo à l'aide de compositions pharmaceutiques comprenant des protéines immunogènes ou des (poly)peptides dérivés de l'IFN? ou leurs séquences nucléotidiques correspondantes.
Buyse Marie-Ange
Depraetere Stany
Lorre Katrien
Innogenetics N.v.
Smart & Biggar
LandOfFree
Treatment of type 1 immune response-mediated inflammatory... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treatment of type 1 immune response-mediated inflammatory..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of type 1 immune response-mediated inflammatory... will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1788928